Nkarta Inc (NKTX)

The $13 Million Company Teaching the Immune System to Hunt CancerMay 29, 2026 9:00 AM
PR Newswire (US) Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three separate drug candidates already dosing patients in human trials, a technology platform exclusively licensed from the University of Minnesota, and a scientific approach that the largest names in cancer immunotherapy are spending billions to pursue. See the full GT Biopharma investor breakdown at USA News Group ?That gap — between what the company is doing in the clinic and what the market is paying for it — is the entire story. Whether it closes, and in which direction, is the question every investor reading this should be weighing right now.The idea: don't build a new weapon, sharpen the one you already haveMost cancer therapies try to bolt something new onto the body — a manufactured cell, a synthetic antibody, a toxic payload. GT Biopharma's approach is different, and once you understand it, it's hard to forget.The human immune system already contains a class of cells whose entire job is to find and destroy abnormal cells: natural killer cells, or NK cells. They are the immune system's first responders, patrolling the body and killing threats without needing to be "trained" first. The problem in cancer is that tumors learn to hide from them. GT Biopharma's platform, called TriKE® — short for Tri-specific Killer Engager — is designed to drag those NK cells directly onto the tumor and switch them on.A TriKE molecule is engineered with three parts joined together. One arm grabs the NK cell by a receptor called CD16. A second arm grabs the cancer cell by a marker on its surface. And in the middle sits a molecule called IL-15, which acts like a shot of adrenaline, keeping the NK cell alive and multiplying once it's locked onto its target. The result, in concept, is elegant: you take the body's existing assassins, handcuff them to the tumor, and tell them to get to work.The platform was developed at the University of Minnesota, and GT Biopharma holds an exclusive worldwide license to develop and commercialize therapies based on it. This is not a science project the company dreamed up in isolation — it's institutional research that GTBP has the rights to turn into medicine.Why now: three shots on goal, all liveWhat changed in 2026 is that GT Biopharma stopped being a one-drug story. As of this spring, the company has advanced three TriKE candidates into the clinic — a milestone its leadership rightly calls a turning point.Track every clinical milestone on the GTBP catalyst timeline ?The lead program is GTB-3650, aimed at relapsed or refractory CD33-positive blood cancers — specifically acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), two of the most treatment-resistant cancers in oncology. It is the first TriKE built on camelid nanobody technology — antibody fragments derived from the same family as llamas and alpacas, prized for being small, stable, and able to penetrate tissue. The Phase 1 dose-escalation trial began enrolling in early 2025 and has moved methodically upward through its dose cohorts. As of the company's Q1 2026 report in May, Cohort 4 enrollment was complete with eight patients treated across the first four cohorts — and, critically, the earlier safety reviews advanced without the dose-limiting toxicities that derail so many early trials. The study can escalate through up to seven cohorts, and management has guided to a meaningful data update in the second half of 2026.The newest program is where the ambition becomes obvious. In May 2026, GT Biopharma dosed the first patient in the Phase 1 trial of GTB-5550, a TriKE targeting a protein called B7-H3. Here is why that matters: B7-H3 is expressed on a huge range of solid tumors, and in metastatic castration-resistant prostate cancer it appears in over 90% of tumors. The trial begins with a prostate-cancer-focused dose escalation, then expands into a "basket" across as many as seven solid tumor types — prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder. In the company's own framing, the solid-tumor patient population GTB-5550 targets is "orders of magnitude larger" than the blood-cancer population of its lead drug. And GTB-5550 uses subcutaneous dosing — a simple injection rather than an infusion — which the company describes as more patient-friendly, a quiet but real commercial advantage if the drug works.Three programs. Two cancers as different as liquid and solid tumors. One underlying platform. That is the shape of a company trying to prove a technology, not just a single molecule.The market it's chasing is enormousThe backdrop here is not subtle. The global oncology market is projected to nearly double from roughly $139 billion in 2025 to about $268 billion by 2034. Solid tumors alone represent a market estimated in the hundreds of billions of dollars, and B7-H3 — GTB-5550's target — shows up across many of the most common and lethal of them. NK-cell-directed immunotherapy has become one of the most closely watched frontiers in the entire sector, precisely because it offers the prospect of harnessing the immune system with potentially fewer of the brutal side effects of conventional treatment.Why NK-cell therapy is biotech's hottest frontier — read the deep dive ?When a tiny company is pointed at a market that large, the math of asymmetry takes over. It does not require GT Biopharma to win the whole field. It requires only that one of its three shots connects — and that the market eventually notices a company priced near $13 million is playing in an arena measured in the hundreds of billions.How GT Biopharma stacks up against its NK-cell peersThe most useful way to understand GTBP's positioning is to look at the company it keeps. NK-cell and immune-engager therapy is a crowded, well-funded field — and the contrast in scale is the entire investment argument.ImmunityBio (NASDAQ: IBRX) is the proof of concept that NK-cell immunotherapy can reach the market. Its NK-activating therapy ANKTIVA is FDA-approved for bladder cancer, the company reported roughly $44 million in product revenue in Q1 2026 and held some $381 million in cash, and it is now scaling NK-cell manufacturing to billions of cells per batch. ImmunityBio is what NK-cell success looks like at commercial scale — and a reminder of the valuation gap a clinical-stage peer could theoretically narrow if its data delivers.Fate Therapeutics (NASDAQ: FATE) is the deep-pocketed platform play, engineering off-the-shelf NK and CAR-T cell therapies from induced pluripotent stem cells, with roughly $175 million in cash and a runway management has guided into 2028. Fate illustrates how richly the market will fund an NK/cell-therapy platform it believes in — a striking counterpoint to GTBP's microcap valuation.Nkarta (NASDAQ: NKTX) is the engineered-NK-cell specialist, advancing its platform into autoimmune disease and backed by a market capitalization and cash position orders of magnitude above GT Biopharma's. Nkarta shows that NK-cell companies can command substantial valuations well before commercialization, on the strength of platform potential alone.Artiva Biotherapeutics (NASDAQ: ARTV) rounds out the set as the allogeneic, off-the-shelf NK-cell developer whose lead candidate AlloNK is heading toward a Phase 3 registrational trial in refractory rheumatoid arthritis in 2026. Artiva demonstrates how far and how fast an NK-cell program can advance through the clinic — the kind of trajectory GTBP investors are betting its TriKE platform can follow.Set GT Biopharma beside those four names and the picture sharpens. They are pursuing variations of the same fundamental thesis — unleash NK cells against disease — and the market has assigned them valuations ranging from the hundreds of millions into the billions. GT Biopharma, with three candidates already in the clinic, sits near $13 million. Either the market has correctly priced a struggling microcap, or it has badly overlooked a platform company in the same arena as far larger peers. That is the bet, stated plainly.The risks, stated honestlyNo serious investor case is complete without the other side of the ledger, and GT Biopharma's is real.This is a clinical-stage company with no approved products and no product revenue. Its cash balance was approximately $9 million at the end of Q1 2026, which management expects to fund operations only through the fourth quarter of 2026 — meaning additional financing, likely dilutive to existing shareholders, is a near-certainty rather than a possibility. The stock trades well under a dollar and far below its 52-week high, and a Roth Capital analyst, while maintaining a Buy rating, cut the price target to $3 from $8 earlier this year. Phase 1 trials are designed to test safety, not to prove a drug works; the encouraging absence of dose-limiting toxicities and the early signs of NK-cell activation are genuinely positive, but they are not efficacy. Most drugs that enter Phase 1 never reach the market. And the very peers that make GTBP look cheap are also formidable competitors with vastly greater resources.In short: this is a high-risk, binary-outcome situation. It is exactly the kind of company that can multiply many times over on a single strong data readout — and exactly the kind that can be forced into painful dilution or worse if the data disappoints or the financing window closes. Both outcomes are live.The bottom lineGT Biopharma is a study in asymmetry. On one side: a roughly $13 million valuation, a sub-dollar stock, a thin cash runway, and all the risk that comes with clinical-stage biotech. On the other: three drugs dosing patients, a platform licensed from a top-tier research university, a mechanism the biggest players in immuno-oncology are validating with their own R&D budgets, and a pair of catalysts — GTB-3650 data and GTB-5550 progress — both expected in the second half of 2026.That is the setup. A company priced for failure, sitting on a platform built for something much larger, with hard data events on the calendar in a matter of months. For investors who understand that the biggest biotech returns come from the names the market has written off just before it's forced to reconsider, GT Biopharma is a story worth watching very closely between now and year-end.Get the full GTBP investor profile, pipeline, and catalyst calendar at USA News Group ?CONTACT:
USA News Group
info @therooster-2873Sources:GT Biopharma, Inc., "GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors," GlobeNewswire, May 14, 2026.GT Biopharma, Inc., "GT Biopharma Reports First Quarter 2026 Financial Results," May 15, 2026 (Cohort 4 complete, 8 patients across first four cohorts; ~$9M cash to Q4 2026; 2H 2026 updates).GT Biopharma, Inc., IND submission / pipeline overview — TriKE mechanism (camelid anti-CD16 / scFv anti-CD33 / IL-15), GTB-3650 dose-escalation design (up to 7 cohorts, ~14 patients), GTB-5550 design and B7-H3 >90% in mCRPC; gtbiopharma.com product pipeline.Roth Capital analyst note (Jonathan Aschoff), price target revised to $3 (Buy), 2026.Global Market Insights Inc. oncology market size ($139.4B 2025 ? $268.3B 2034); Data Bridge Market Research solid-tumor market context.ImmunityBio (NASDAQ: IBRX) Q1 2026 results and NK-cell manufacturing release, 2026.Fate Therapeutics (NASDAQ: FATE) Q1 2026 results (runway into 2028), May 13, 2026.Nkarta (NASDAQ: NKTX) corporate/clinical disclosure, 2026.Artiva Biotherapeutics (NASDAQ: ARTV) corporate disclosure / AlloNK Phase 3 plan, 2026.DISCLAIMER:Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed by USA News Group on behalf of MIQ. MIQ has been paid a fee for GT Biopharma, Inc. advertising and digital media from Creative Direct Marketing Group ("CDMG"). There may be 3rd parties who may have shares of GT Biopharma, Inc. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. The owner/operator of MIQ currently owns shares of GT Biopharma, Inc. that were purchased in the open market and reserves the right to buy and sell, and will buy and sell shares of GT Biopharma, Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of GT Biopharma, Inc. by CDMG; this is a digital media distribution.While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.Logo: https://mma.prnewswire.com/media/2838876/5656770/USA_News_Group_Logo.jpg  View original content:https://www.prnewswire.com/news-releases/the-13-million-company-teaching-the-immune-system-to-hunt-cancer-302785505.htmlSOURCE USA News Group Original: The $13 Million Company Teaching the Immune System to Hunt Cancer

NKTX.................................https://stockcharts.com/sc3/ui/?s=NKTX&p=W&b=5&g=0&id=p86431144783

NKTX..........https://stockcharts.com/h-sc/ui?s=NKTX&p=W&b=5&g=0&id=p86431144783

NKTX.........................................................https://stockcharts.com/h-sc/ui?s=NKTX&p=W&b=5&g=0&id=p86431144783

Modulus used Fnl4 plus CRTAM (I don't know about CD3z). Nkarta uses OX40 plus CD3z.

Modulus was going to focus on additional screening combinations testing different antigen-binding domains, extracellular domains and transmembrane domains to further enhance the efficacy of its lead anti-CD19 CAR-NK cell therapy.

NKTX.............................https://stockcharts.com/h-sc/ui?s=NKTX&p=W&b=5&g=0&id=p86431144783

NKTX, under $2

From the 10-K: ''In 2021, we entered into a Research Collaboration Agreement with CRISPR (as amended, the "CRISPR Agreement") to establish research plans for the purpose of collaboratively designing and advancing up to two allogeneic, gene-edited NK-cell therapies and one allogeneic, gene-edited NK+T-cell therapy for use in the treatment of autoimmune diseases, oncology, or infectious disease up to the filing of an application to a regulatory authority to request the ability to start a clinical trial. The first product candidate being developed in partnership with CRISPR was NKX070, and together with CRISPR, we had planned to advance NKX070 in clinical development for the treatment of solid tumors and blood cancers. The second product candidate being developed in partnership with CRISPR was NK+T. Both the NKX070 and NK+T programs have been deprioritized, however, to allow us to focus our resources on developing NKX019 for the treatment of B-cell mediated autoimmune diseases.''

NKTX.................................https://stockcharts.com/h-sc/ui?s=NKTX&p=W&b=5&g=0&id=p86431144783

Anyone know of a reason for NKTX's decline today?

Some slides

An ACR LBA https://acrabstracts.org/abstract/allogenic-cd19-car-nk-cells-therapy-in-refractory-systemic-lupus-erythematosus-an-open-label-single-arm-prospective-and-interventional-clinical-trial/

NKTX under $7

An update https://www.fiercebiotech.com/biotech/preclinical-gene-editor-tome-laying-131-staffers-virtually-entire-workforce

NKTX under $10

I assume (rightly or wrongly) that expression of HLA class I and II will be disrupted through genetic ablation of beta 2 microglobulin (B2M) and the class II transactivator (CIITA), respectively, allowing evasion of the patient's adaptive immune system, with the CD38 gene also being ablated as well.

If so, CD38-targeted mAbs, such as daratumumab, are approved for the treatment of multiple myeloma. CD38 has also been shown to be highly expressed on activated immune cells, including CD8+ T-cells, CD4+ T-cells, and NK cells. FATE has incorporated the knock-out of CD38 into some of its iPSC-derived products, which uniquely allows for CD38-null, iPSC-derived cells to be combined with CD38-targeted mAbs and avoid fratricide. In one ASH presentation [1], scientists from the company showed that the administration of daratumumab selectively depleted allogeneic CD38+ NK and T-cells and uniquely enabled CD38-null iNK cells to functionally persist through Day 28 compared to non-edited iNK cells. These preclinical data were supported by translational findings from the PhI trial of FT576, its multiplexed-engineered, BCMA-targeted CAR-NK cell product candidate that incorporates the knock-out of CD38, where combination with daratumumab rapidly and selectively eliminated CD38+ patient immune cells through the first month of therapy. The translational findings suggest that following administration of daratumumab, CD38-null iNK cells may avoid rejection by activated host immune cells without requiring conditioning chemotherapy.

Ref:
1 https://ashpublications.org/blood/article/140/Supplement%201/7388/492103/iPSC-Derived-CD38-Null-NK-Cells-in-Combination

Some more info https://tome.bio/wp-content/uploads/2024/05/ASGCT-2024-Podium-Talk-FINAL.pdf

(OT) Last week, Tome Bio dis­closed its pipeline for the first time. Its two most ad­vanced pro­grams are a pair of off-the-shelf cell ther­a­pies for au­toim­mune kid­ney dis­eases, in­clud­ing lu­pus nephri­tis. The en­gi­neered NKs are among the most heav­i­ly edit­ed, with three genes knocked out and four to five genes added.

NKTX under $10

(OT) From Modulus Therapeutics (before DNA had acquired its cell therapy platform assets). The OX40 co-stim domain is used by Nkarta.

(OT) A post on LinkedIn by Max Qian (CEO and Co-Founder at Rui Therapeutics):

''I am so pleased today to share an exciting clinical development with our CAR-NK therapeutic platform on Autoimmune disease space. Attached six slides describe our ongoing FIH clinical trial of KN5501 (CD19 CAR-NK) that is used to treat three severe SLE (systemic lupus erythematosus) patients. We innovatively designed this dose-escalation clinical trial with 1+2+3=6 patients to complete low, medium and high dose.
SLEDAI 2K score (SLE disease activity index 2000), the most commonly used system that evaluates the severity of SLE, is used to determines changes in the disease activity of patients diagnosed with SLE: 1) mild activity (SLEDAI-2K = 6); 2) moderate activity (SLEDAI-2K 7 to 12); 3) severe activity (SLEDAI-2K>12).
· The higher the score, the more significant is the degree of disease activity.
· Scores of 6 and above are considered to be consistent with active disease requiring therapy. However, scores greater than 20 are very rare.
· Modifications of score of 6 (improvement) and of 8 (worsening) are considered clinically relevant.

Consistently, as we observed in r/rDLBCL trials, CAR-NK demonstrated a supper safety profile, i.e., no CRS nor ICANS. Very most exciting is that we observed the efficacy from the 1st three patients on low and medium dose (we even have not completed three doses with medium dose patients yet!). This might be the very 1st FIH data available globally to support CAR-NK therapy in SLE.

In earlier this year, we may hear CAR-T on SLE, but latest FDA announcement may give us (patients, hospital and manufacturers) a 2nd thought of the CAR-T approach in autoimmune disease spaces; don’t mention its other safety and economic concerns. Welcome discussions!''

..

Companies usually raise cash after positive (trial) results. This secondary was on the promise in autoimmune https://www.globenewswire.com/news-release/2024/03/25/2851470/0/en/Nkarta-Announces-Pricing-of-240-Million-Underwritten-Offering.html

Brutal https://www.oncologypipeline.com/apexonco/another-false-dawn-nkarta

AACR abstracts

3603 / 9 - NKX101, an allogeneic off-the-shelf CAR NK cell therapy targeting NKG2D-Ls, has potent anti-leukemic activity alone or in combination with Ara-C https://www.abstractsonline.com/pp8/#!/20272/presentation/7138

3604 / 10 - NKX101, an allogeneic off-the-shelf NKG2D CAR-NK cell therapy, has potent in vitro cytotoxicity against patient-derived AML leukemic stem cells and non-leukemic stem cell blasts https://www.abstractsonline.com/pp8/#!/20272/presentation/7139

AFMD has been hit with the CEO going, and CMO acting as the interim, both the CSO and CFO resigning, and R/S. Let's hope the data is positive as times remain tough in the NK field. If so, investors should probably expect a cash raise.

As for NKTX, hope they start selecting optimal donors and testing ML NKs, especially for solid tumours https://aacrjournals.org/clincancerres/article/27/17/4859/671641/Memory-like-Differentiation-Enhances-NK-Cell https://aacrjournals.org/cancerres/article/83/7_Supplement/893/719928/Abstract-893-Memory-like-differentiation-enhances

NKTX new 52 week high

NKTX new 52 week high

NKTX new 52 week high

I’m at $7.10 just sold half at 10 in less than 20 minutes

Wowsers am I the only one here

MF SZ CTCL must be the best friend for bios. TRIL, AFMD, ... all had good response with their CD47, CD30 ..

There it goes as expected. NKTX selling off.

Yuppers trust the Nickle

Thanks for heads up this is going nuts lol

Boom

Nkarta's Stock Climbs 28% After FDA Approves Drug Application

Nkarta's shares rallied after the company said its investigational new drug application for NKX019, a treatment for lupus nephritis, was approved by the U.S. Food and Drug Administration.

The stock climbed 28% to $1.89 in late morning trading Tuesday. The stock hit a 52-week low of $1.28 earlier this month, and the shares are down 69% this year.

The company said its multi-center, open label, dose escalation clinical trial will assess the safety and clinical activity of NKX019 in patients with refractory lupus nephritis.

Nkarta, a biopharmaceutical company based in South San Francisco, Calif., said it is a developer of engineered natural killer cell therapies.

Lupus nephritis is a form of systemic lupus erythematosus, and is developed by about 40% of the estimated 200,000 people in the U.S. diagnosed with the disease. Of that group, 30% will develop end stage kidney disease, which can be fatal unless they receive dialysis or a kidney transplant.

https://ih.advfn.com/stock-market/NASDAQ/nkarta-NKTX/stock-news/92295683/nkartas-stock-climbs-28-after-fda-approves-drug-a

$NKTX

NKTA under $2

Updated

With all the edits, CAR NK is more like ADC, not NK cells that have also been described as ‘immune-regulatory’ because of their ability to produce an array of cytokines and chemokines, through which they help shape B cell and T cell responses, and impact the function of DC, macrophages and neutrophils

More from $NKTX hopes to avoid the fate of $FATE, via @evaluatevantage -> https://t.co/1SOK7gOAbS— Jacob Plieth (@JacobPlieth) June 27, 2023

PR https://finance.yahoo.com/news/nkarta-updates-clinical-progress-car-110100481.html

Slides https://ir.nkartatx.com/static-files/681c0391-4a87-453b-91a5-2af3e6d3f477

The update will be today at 8:00 a.m. ET https://nkx101-clinical-update-conference-call.open-exchange.net/registration

PR https://www.globenewswire.com/news-release/2023/04/17/2648511/0/en/Nkarta-Presents-Preclinical-Data-Exploring-Gene-Knockout-Strategies-and-Combination-Agents-with-NK-Cell-Based-Therapies-at-the-2023-AACR-Annual-Meeting.html

Posters https://www.nkartatx.com/file.cfm/75/docs/nkarta_aacr2023_poster%20890_adam17%20ko%20of%20nk%20cells.pdf https://www.nkartatx.com/file.cfm/75/docs/nkarta_aacr2023_poster%203183_nkx101%20and%20cetuximab%20combo.pdf

Yes, it could have been primary resistance due to low MICA/B (or other NKG2DLs) expression, but without any translational data from the company there is no way of knowing.

Disfunctional NKs have a few more mutations than dysfunctional NKs.

My point was MDS patients has disfunctional NK cells which cause the cancer to slow down on MICA expression. With lowered MICA expression, NKTX cells don't work. I doubt MDS TME is more suppressive than AML.

In patient's there is immune cell dysfunction, but using off-the-shelf should be able to overcome some of that. As for primary, adaptive and/or acquired resistance, only translational data will be able to give insights as to what strategies could combat that.

Yes, just a shame about the target.